公开(公告)号：US20240309016A1

公开(公告)日：2024-09-19

申请号：US18606857

申请日：2024-03-15

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Mitsunori KONO ,  Yusuke SASAKI ,  Yuya OGURO ,  Zenichi IKEDA ,  Osamu KUBO ,  Masaki SETO ,  Toru YAMASHITA ,  Makoto KAMATA ,  Kenjiro SATO ,  Matthew Thomas REYNOLDS ,  Kazuaki TAKAMI ,  Asato KINA ,  Takafumi YUKAWA ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Keiko KAKEGAWA ,  Takuto KOJIMA ,  Florian PÜNNER ,  Masataka MURAKAMI ,  Takahiko TANIGUCHI ,  Tatsuki KOIKE ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Yasushi HATTORI ,  Eiji KIMURA ,  Martin Alexander PAWLICZEK ,  Marilena PIRA ,  Shuhei IKEDA ,  Noriyuki TEZUKA ,  Yoshikazu WATANABE ,  Kevin CURRAN ,  Nicolle DOERING ,  Maria HOPKINS ,  Ben JOHNSON ,  Andre KIRYANOV ,  Jon LAM ,  Sean MURPHY ,  Natasha O'ROURKE ,  Holly REICHARD ,  Paul TANIS ,  Yunlong ZHANG

IPC分类号： C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

CPC分类号： C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230028114A1

公开(公告)日：2023-01-26

申请号：US17753803

申请日：2020-09-15

申请人： Holger MONENSCHEIN ,  Sean MURPHY ,  Scott OLSEN ,  Natasha O'ROURKE ,  Holly REICHARD ,  Melinda DAVIS ,  Betty LAM ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Holger MONENSCHEIN ,  Sean MURPHY ,  Scott OLSEN ,  Natasha O'ROURKE ,  Holly REICHARD ,  Melinda DAVIS ,  Betty LAM

IPC分类号： A61K31/5025 ,  C07D471/04

摘要： Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 and X7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.